Vasomotor Symptoms Market By Treatment Type (Menopausal Hormone Therapy, Non-Hormonal Prescription Medications), By Hormone Therapy Type (Estrogen-Only Therapy, Combined Estrogen + Progestogen Therapy), By Non-Hormonal Drug Class (Neurokinin Receptor Antagonists, SSRIs/SNRIs, Neurologic Medications), By Care Setting (Primary Care & Outpatient Clinics, Gynecology & Menopause Clinics, Hospitals, Oncology Clinics), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Vasomotor Symptoms Market: Global Epidemiology, Treatment Landscape, Utilization Gaps & Growth Analysis

The Global Vasomotor Symptoms Market was valued at USD 3.92 billion in 2025 and is projected to reach USD 6.38 billion by 2032, growing at a CAGR of 7.2% during 2026–2032, according to Strategic Market Research.

 

Vasomotor Symptoms (VMS) primarily encompass menopausal hot flashes and night sweats—episodes of sudden heat, flushing, and sweating caused by thermoregulatory instability in the brain during the menopausal transition—severe or persistent enough to generate treatment demand. The commercial opportunity is centered on prescription hormone therapy and nonhormonal prescription treatments rather than on the broader menopause-care category.

 

Fezolinetant (Veozah) and low-dose paroxetine mesylate (Brisdelle) are FDA-approved non-hormonal treatments for moderate-to-severe menopausal vasomotor symptoms such as hot flashes and night sweats, used alongside traditional hormone therapy (estrogen/progestin). Fezolinetant works as an NK3 receptor antagonist by blocking neurokinin B signaling on KNDy neurons in the hypothalamus, helping restore normal thermoregulatory control disrupted by estrogen decline. Paroxetine mesylate, an SSRI, reduces symptoms by inhibiting serotonin reuptake and modulating central thermoregulatory pathways involved in hot flashes. In contrast, hormone therapy directly replaces declining estrogen (with progestin added when the uterus is present) to stabilize the hypothalamic temperature regulation center and address the underlying hormonal trigger of vasomotor symptoms.

 

More than half of women aged 40–64 worldwide experience vasomotor symptoms (hot flashes and night sweats), yet only a small portion receive treatment due to safety concerns and low treatment-seeking behavior. The condition affects a very large population, with over 1.2 billion women expected to be postmenopausal globally by 2030 and about 56 million women in the U.S. currently in or approaching menopause, with over 1 million new cases each year. The severity of symptoms also varies by region, with moderate-to-severe cases seen in about 40% of women in Europe, 34% in the U.S. (and up to 46% in some estimates), and 16% in Japan. On average, symptoms last for around 7.4 years, meaning many women experience long-term discomfort, but despite this burden, most remain untreated or do not use available therapies.

 

A Large Symptomatic Population Still Does Not Translate Into Equivalent Treatment Utilization

The largest expansion opportunity in the Vasomotor Symptoms Market remains the gap between women experiencing disruptive symptoms and those receiving prescription treatment.

A 2024 PatientsLikeMe survey involving 196 U.S. women with VMS found that 87.2% considered their symptoms bothersome, while 54.3% reported daytime hot flashes and 59.2% experienced nighttime sweats or hot flashes. Despite this burden, only 35.2% were being treated for their symptoms. Among respondents receiving prescription treatment, hormone therapy was the most commonly reported option, accounting for 58%.

A separate U.S. real-world medical-record study covering 1,016 women presenting with bothersome hot flashes found that 60.1% had a prescription medication documented, meaning almost 40% had no documented prescription. Approximately half had delayed seeking care for more than six months despite experiencing bothersome symptoms.

The multinational REALISE study provides a similar commercial picture. Among women with moderate-to-severe VMS across the United States and five major European markets, hormone therapy was the most commonly prescribed pharmacological treatment at 49.8%, while serotonergic antidepressants accounted for 15.7%. Nearly one-third of women with moderate-to-severe symptoms had never received treatment despite having access to healthcare.

 

Therapy Utilization, Efficacy & Clinical Outcomes

Menopausal hormone therapy (MHT or HRT) is considered the most effective treatment for hot flashes and other menopause symptoms, but its use has dropped sharply over time. Before 2002, about 22%–27% of eligible postmenopausal women in the U.S. used hormone therapy. However, after early findings from the Women’s Health Initiative study raised safety concerns, usage fell dramatically to around 4%–6%.

Today, use is even lower. By 2023, only about 1.7% of symptomatic women in the U.S. were using hormone therapy, and even among healthy women aged 50–59, the rate was just 3.5%. In comparison, uptake is slightly higher in Europe, with about 14% of menopausal women in the U.K. using MHT for symptom relief.

Despite being clinically effective, most women avoid hormone therapy. Surveys show that more than half of symptomatic women in the U.S. and Europe, and nearly 80% in Japan, are reluctant to use it, even if they are medically eligible. Only a small share (about 8%–12%) cannot use it due to medical reasons, meaning the majority of low usage is driven by fear or preference rather than strict medical restrictions.

 

Non-Hormonal Prescription Treatment Landscape

Many women avoid menopausal hormone therapy (MHT) due to safety concerns or personal preference, so non-hormonal treatments are becoming an increasingly important part of care for vasomotor symptoms like hot flashes and night sweats. These options are gaining attention because they offer alternatives for women who either cannot or do not want to use hormones.

One key group of treatments is neurokinin receptor antagonists, such as fezolinetant, which have shown about a 20% to 25% greater reduction in hot flash frequency and severity compared to placebo in clinical studies. Another commonly used option includes low-dose antidepressants (SSRIs and SNRIs) like escitalopram and venlafaxine, which can reduce hot flashes by about 10% to 25% compared to placebo.

Despite the availability of these therapies, there is still a major treatment gap. Research from the multi-country REALISE study shows that around one-third (33%) of women with moderate-to-severe symptoms have never received any treatment at all, even though they have access to healthcare. This highlights both the growing role of non-hormonal therapies and the large unmet need in managing menopausal symptoms.

 

Hormone Therapy Retains Market Leadership Despite Rapid Nonhormonal Innovation

Hormonal treatment accounted for an estimated 68.4% of the Vasomotor Symptoms Market in 2025, equivalent to approximately USD 2.68 billion. Its leadership reflects an established prescribing base, multiple formulations, extensive physician familiarity, and continued use for bothersome menopausal symptoms.

Current prescribing data indicate that this segment is still expanding. NHS Business Services Authority data show that England recorded 14.7 million HRT prescription items in 2024/25, an increase of 11% from the previous year. The estimated number of identified patients receiving HRT increased from 2.6 million to 2.8 million, representing growth of 6.4%. Estradiol 0.06% gel alone accounted for approximately 1.3 million prescribed items.

A significant U.S. regulatory change in 2026 could further influence prescribing behavior. In February 2026, the FDA approved labeling changes for an initial group of menopausal hormone-therapy products that removed statements concerning cardiovascular disease, breast cancer, and probable dementia from the boxed warning. The agency retained other product-specific warnings and did not remove cardiovascular and breast-cancer risks from the broader Warnings and Precautions sections.

The commercial effect could be greater willingness among appropriate patients and physicians to reconsider HRT after years of risk-sensitive prescribing. This creates an important counterbalance to the emergence of premium nonhormonal drugs. The VMS market is therefore not developing through simple replacement of HRT. Instead, it is separating into an established hormonal pathway and an expanding nonhormonal pathway for women who cannot use hormones, prefer not to use them, discontinue HRT, or remain inadequately controlled.

 

Menopausal Hormone Therapy (MHT / Hormone Replacement Therapy)

Menopausal hormone therapy (MHT) is the most effective treatment for hot flashes and night sweats, working by replacing declining estrogen during menopause. It is available as oral pills, patches, gels, and sprays, and includes estrogen-only therapy for women without a uterus and combined estrogen–progestogen therapy for those with an intact uterus. Clinical guidelines state that for healthy symptomatic women under 60 or within 10 years of menopause, benefits generally outweigh risks, with transdermal options like patches carrying a lower blood clot risk than oral forms.

 

Neurokinin Antagonists Are Forming a Competitive Nonhormonal Prescription Category

The introduction of neurokinin antagonists represents the most important pharmaceutical change in the VMS market in recent years.

In May 2023, the FDA approved Astellas' VEOZAH (fezolinetant) for moderate-to-severe VMS caused by menopause. The approval established the first NK3 receptor antagonist specifically indicated for menopausal VMS and created a purpose-built oral nonhormonal option rather than relying primarily on hormone therapy or repurposed medicines.

European regulators subsequently authorized fezolinetant as VEOZA. EMA data from two studies involving more than 1,000 women showed that moderate-to-severe daily hot flashes declined by an average of 53% after four weeks with fezolinetant 45 mg compared with 32% with placebo. At 12 weeks, the reductions were 63% and 40%, respectively.

Commercial adoption followed. FDA estimated that approximately 28,700 U.S. patients had been dispensed VEOZAH through outpatient retail pharmacies by May 2024, demonstrating meaningful early utilization.

Safety monitoring subsequently became an important commercial consideration. In December 2024, FDA added a Boxed Warning for rare but serious liver injury to VEOZAH. Current recommendations require liver-function testing before treatment, monthly during the first three months, and again at months six and nine. These requirements introduce additional physician, laboratory, and patient follow-up steps that can influence initiation and persistence.

Despite this monitoring burden, Astellas continues to report growth. During April–June FY2026, U.S. VEOZAH revenue reached USD 79 million, up 32.2% year over year, compared with USD 59 million in the previous-year quarter. Revenue across Astellas' Established Markets, including Europe and Canada, increased from approximately EUR 5 million to EUR 10 million.

This commercial performance demonstrates that VMS-specific nonhormonal treatment has moved beyond experimental market development into a measurable pharmaceutical category with dedicated prescribing, reimbursement negotiations, physician promotion, safety-management requirements, and recurring product revenue.

Non-hormonal prescription medications are mainly used for women who cannot or prefer not to use hormone therapy due to risks such as blood clots, liver disease, or hormone-sensitive cancers. The newest and most targeted option is neurokinin receptor antagonists, such as fezolinetant (Veozah) and elinzanetant, which work by acting on the brain’s temperature control center to reduce hot flashes and night sweats. These drugs are effective but require regular liver function monitoring.

Other non-hormonal options include low-dose antidepressants (SSRIs and SNRIs) like paroxetine, venlafaxine, and escitalopram, which help reduce hot flashes by adjusting brain chemistry, and neurologic medications such as gabapentin and pregabalin, which are sometimes used off-label, especially for nighttime symptoms. Together, these therapies provide alternative treatment pathways for managing vasomotor symptoms without using hormones.

Lifestyle and behavioral strategies can help improve the management of vasomotor symptoms, although they may not fully eliminate severe hot flashes. Evidence supports Cognitive Behavioral Therapy (CBT), which helps reduce the perceived severity and distress of symptoms by modifying stress responses and coping mechanisms. In addition, core temperature management techniques—such as wearing light, layered clothing, using fans, adjusting room temperature, and avoiding triggers like spicy foods, caffeine, and alcohol—can help reduce the frequency and intensity of hot flashes and improve overall symptom control.

 

Direct Astellas-Bayer Competition Is Reshaping the Nonhormonal Segment

The competitive structure changed materially when Bayer entered the market with LYNKUET (elinzanetant). FDA approved the therapy in October 2025 for moderate-to-severe VMS due to menopause, ending Astellas' position as the only major company commercializing a dedicated neurokinin-targeted treatment in the United States.

The two companies now compete for a relatively well-defined patient population: women with moderate-to-severe VMS who require prescription treatment but for whom HRT is unsuitable, unwanted, discontinued, or otherwise not preferred.

Astellas benefits from a first-mover advantage, an established U.S. prescriber base, accumulated post-launch experience, and measurable VEOZAH sales. Its disadvantage is the liver-monitoring requirement, which introduces additional treatment-management burden.

Bayer is entering later but with a differentiated product and substantial commercial resources. LYNKUET acts as a dual NK1/NK3 receptor antagonist, while fezolinetant selectively targets NK3 receptors. Bayer's H1/Q2 2026 financial reporting also shows increasing pharmaceutical selling expenses associated partly with marketing investment behind LYNKUET, indicating that the company is actively spending to build prescriber awareness and accelerate launch adoption.

Europe provides Bayer with an additional competitive angle. EMA authorized LYNKUET not only for moderate-to-severe menopausal VMS but also for VMS resulting from adjuvant endocrine therapy for breast cancer. This creates a route into oncology-associated symptom management and gives Bayer access to a clinically distinct population outside conventional menopause practice.

Real-world research indicates meaningful demand in this population. A REALISE analysis involving breast-cancer survivors receiving endocrine therapy classified 68.0% of 617 surveyed women as having moderate-to-severe VMS, while 66.9% of that subgroup reported receiving treatment.

Competitive advantage will therefore depend on more than clinical efficacy. Payer coverage, safety-monitoring requirements, physician familiarity, treatment persistence, indication breadth, and formulary positioning are likely to determine which neurokinin antagonist gains greater share.

Competition may also expand the total market rather than merely redistribute existing prescriptions. Astellas and Bayer both have commercial incentives to increase menopause consultations, improve physician awareness of nonhormonal treatment, identify previously untreated patients, and strengthen reimbursement pathways. Category promotion by two large pharmaceutical companies can consequently increase the number of women entering prescription treatment.

 

North America Sets the Commercial Benchmark While Europe Becomes the Reimbursement Test Market

North America

North America currently represents the most commercially developed market for VMS-specific pharmaceutical innovation, led by the United States, accounting for approximately 45% market share in 2025, valued at around USD 1.76 billion, and is projected to expand at a CAGR of nearly 7.5% during 2026–2032.

The U.S. was the first major market to approve fezolinetant in 2023 and subsequently approved elinzanetant in October 2025. Astellas' USD 79 million in U.S. VEOZAH revenue during April–June 2026 provides direct evidence that neurokinin-targeted VMS treatment has established a meaningful commercial base.

The United States is also entering a more competitive phase because physicians now have two dedicated neurokinin therapies rather than a single branded entrant. At the same time, the FDA's 2026 HRT labeling changes could make hormone treatment more acceptable among clinically appropriate women.

 

Europe

Europe is emerging as the most important reimbursement and health-technology-assessment market for newer VMS therapies, accounting for an estimated ~30–32% share of the global Vasomotor Symptoms Market in 2025, representing a market size of approximately USD 1.15–1.25 billion, and is projected to grow at a CAGR of ~6.8–7.0% through 2032.

England provides one of the clearest examples. NHSBSA recorded 14.7 million HRT prescription items and 2.8 million identified HRT patients during 2024/25, showing that menopause treatment already has a substantial healthcare-system footprint.

NICE’s subsequent decision to recommend fezolinetant for women for whom HRT is unsuitable adds a second publicly reimbursed pathway. Its estimate that approximately 500,000 women in England may be eligible demonstrates the potential scale of nonhormonal treatment even under restricted criteria.

The region is also strategically important for Bayer because EMA's LYNKUET authorization covers both conventional menopausal VMS and VMS associated with adjuvant endocrine therapy for breast cancer.

European revenue development will nevertheless remain strongly influenced by national HTA decisions. Approval at the EMA level does not automatically translate into unrestricted commercial access across individual countries. Cost-effectiveness thresholds, negotiated pricing, treatment restrictions, and formulary policies will shape uptake more heavily than in predominantly private or mixed-payer markets.

 

Asia-Pacific

Asia-Pacific represents a longer-term expansion opportunity rather than the most mature current revenue pool, accounting for approximately 28% of the global Vasomotor Symptoms Market in 2025, valued at around USD 1.1 billion, and is projected to grow at a CAGR of 8.5% during 2026–2032, driven by increasing menopause awareness, improving healthcare access, and gradual adoption of both hormonal and emerging non-hormonal therapies.

Australia approved VEOZA in February 2024 for moderate-to-severe VMS associated with menopause. The Therapeutic Goods Administration subsequently strengthened warnings concerning hepatotoxicity in 2025, demonstrating how post-marketing safety developments can influence adoption conditions internationally.

Commercial development will depend on country-specific regulatory approvals, reimbursement, physician familiarity with menopause treatment, availability of specialist care, and patient willingness to seek pharmacological treatment.

 

Rest of the World

Latin America, the Middle East, and Africa currently offer a smaller documented opportunity for premium VMS-specific medicines. Treatment remains affected by differences in healthcare access, menopause consultation rates, private-pay capacity, availability of branded drugs, and national reimbursement structures. The region accounted for approximately 12% share of the global VMS market in 2025, valued at ~USD 0.47 billion, and is projected to grow at a CAGR of ~5.8% through 2032.

 

Transitioning From a Single HRT-Dominated Model to a Dual-Therapy Structure

The Vasomotor Symptoms Market is a prescription-driven segment where women with moderate-to-severe symptoms typically move from symptom recognition to medical consultation in outpatient settings such as primary care, gynecology, menopause clinics, and oncology. The care pathway generally progresses from symptoms to diagnosis, treatment eligibility, prescription initiation, and either continued use or switching therapies.

Treatment is mainly divided into two pathways. Hormone therapy (HRT) remains the most established option due to physician familiarity, multiple formulations, and improving confidence following recent regulatory updates, including FDA label changes in 2026 that softened earlier risk warnings for some products. However, overall use remains relatively low compared to the size of the symptomatic population.

The second pathway is nonhormonal therapy, led by newer drugs such as VEOZAH (fezolinetant, Astellas) and LYNKUET (elinzanetant, Bayer). These treatments target women who cannot or prefer not to use hormones, including those with contraindications or treatment aversion. Early adoption is growing, supported by reimbursement decisions such as NICE’s recommendation of fezolinetant in England, which identified around 500,000 eligible women under restricted use criteria.

Both treatment pathways are expected to coexist: HRT remains cost-effective and widely used, while nonhormonal therapies are expanding access for a large underserved patient group.

 

Analyst Perspective: Treatment Conversion Will Determine the Market's 2032 Potential

The key growth driver is not the number of women experiencing symptoms, but how many actually move into diagnosis and treatment and stay on therapy.

Recent data shows this shift is already happening. In the UK, about 2.8 million women were on hormone therapy in 2024/25, while around 500,000 women were identified as eligible for newer nonhormonal treatment options. In the U.S., Astellas reported 32.2% year-over-year growth in VEOZAH sales (Q2 2026), showing rising adoption of targeted nonhormonal therapy.

Overall, treatment is expanding across both hormone and nonhormone options. Updated safety labeling for hormone therapy may support renewed use in suitable patients, while newer drugs are gaining traction among women who cannot or prefer not to use hormones.

Overall, the market is shifting toward broader treatment uptake across both therapy types, with growth depending on how many untreated women enter care and how widely newer therapies are adopted and reimbursed.

 

Vasomotor Symptoms Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.92 Billion
Revenue Forecast in 2032	USD 6.38 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Hormone Therapy Type, By Non-Hormonal Drug Class, By Care Setting, By Geography
By Treatment Type	Menopausal Hormone Therapy [MHT/HRT], Non-Hormonal Prescription Medications
By Hormone Therapy Type	Estrogen-Only Therapy, Combined Estrogen + Progestogen Therapy
By Non-Hormonal Drug Class	Neurokinin Receptor Antagonists, SSRIs/SNRIs, Neurologic Medications
By Care Setting	Primary Care & Outpatient Clinics, Gynecology & Menopause Clinics, Hospitals, Oncology Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large untreated symptomatic population, rising menopause awareness and treatment-seeking, growing adoption of non-hormonal neurokinin receptor antagonists, continued use of menopausal hormone therapy, expanding reimbursement for newer VMS therapies
Customization Option	Available upon request